Last reviewed · How we verify
Binimetinib Oral Tablet
MEK1/2 inhibitor
MEK1/2 inhibitor Used for Melanoma.
At a glance
| Generic name | Binimetinib Oral Tablet |
|---|---|
| Also known as | Mektovi |
| Sponsor | Pierre Fabre Medicament |
| Drug class | MEK inhibitor |
| Target | MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Binimetinib is a small molecule inhibitor of MEK1 and MEK2, enzymes that are part of the MAPK/ERK signaling pathway. This pathway is involved in cell division and growth, and is often dysregulated in cancer cells.
Approved indications
- Melanoma
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Abdominal pain
Key clinical trials
- Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (PHASE2)
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer (PHASE2)
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (PHASE4)
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (PHASE3)
- MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (PHASE2)
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) (PHASE1, PHASE2)
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Binimetinib Oral Tablet CI brief — competitive landscape report
- Binimetinib Oral Tablet updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI